10-DEAZAAMINOPTERIN: A NEW ARTHRITIS REMITTIVE DRUG

摘要

A double blind clinical trial of 10-deazaaminopterin versus the antirheumatoid drug methotrexate (MTX) established that 10-deazaaminopterin, in addition to being at least equally effective as methotrexate in all respects in ameliorating rheumatoid arthritis in humans, it is superior to methotrexate in controlling joint tenderness, joint pain, joint stiffness, and in improving overall functional level. In accordance with this invention 10-deazaaminopterin is claimed as a more effective disease modifying arthritis remittive drug for the treatment of rheumatoid arthritis in humans.